Journal Logo



Ferrero, S.1, 2; Zaccaria, G. M.1; Barbero, D.1; Evangelista, A.3; Di Rocco, A.4; Re, A.5; Stefoni, V.6; Cavallo, F.1, 2; Vitolo, U.7; Balzarotti, M.8; Rusconi, C.9; da Silva, Gomes M.10; Ghislieri, M.11; Omedè, P.2; Zamò, A.12; Ciccone, G.3; Gattei, V.13; Gaidano, G.14; Cortelazzo, S.15; Ladetto, M.16

doi: 10.1097/01.HS9.0000563272.02759.6b
Poster Session II: Indolent and mantle-cell non-Hodgkin lymphoma - Clinical

1Molecular Biotechnologies and Health Sciences - Hematology Division, Università di Torino

2SC Ematologia I, AOU Città della Salute e della Scienza di Torino

3Unit of Clinical Epidemiology, CPO, Città della Salute e della Scienza, Hospital of Turin, Torino

4Department of Cellular Biotechnologies and Hematology, Sapienza University, Roma

5Division of Hematology, Spedali Civili, Brescia

6Institute of Hematology ”L. e A. Seràgnoli“, University of Bologna, Bologna

7SC Ematologia II, AOU Città della Salute e della Scienza di Torino, Torino

8Division of Hematology, Humanitas Cancer Center

9Division of Haematology, Department of Haematology and Oncology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

10Departamento de Hematologia, Instituto Português de Oncologia, Lisboa, Portugal

11Department of Electronics and Telecommunications of Politecnico of Torino

12Department of Oncology, Pathology, University of Turin, Torino

13Clinical and Experimental Onco-Hematology Unit, IRCCS CRO Aviano-National Cancer Institute, Aviano

14Division of Hematology, Department of Translational Medicine, Novara

15Humanitas/Gavazzeni Cancer Center, Bergamo

16Hematology Division, A.O. SS Antonio e Biagio and Cesare Arrigo, Alessandria, Italy

Back to Top | Article Outline


Despite the improvement in therapeutic schedules, a relevant fraction of mantle cell lymphoma (MCL) patients still experience primary treatment failure. This is due to a deep biological heterogeneity, not adequately dissected by the clinical predictors alone, as the MIPI (MCL International Prognostic Index).

Back to Top | Article Outline


The Fondazione Italiana Linfomi (FIL) MCL0208 trial (NCT02354313) is a prospective, randomized phase III trial comparing lenalidomide maintenance vs observation after an intensive citarabine containing chemo-immunotherapy followed by autologous transplantation in frontline MCL patients <66 years.[Ladetto, ASH 2018] Several biological ancillary studies were planned upfront, prospectively investigating the prognostic impact of putative biomarkers. Here we present a comprehensive analysis of the clinical impact of all the identified biopredictors.

Back to Top | Article Outline


Trial details, as well as methods for immunohistochemistry, flow cytometry (FC), immunoglobulin heavy chain (IGH) gene sequencing and minimal residual disease (MRD) analysis have been presented.[Ferrero, ASH 2018] The “BCR-high” gene expression signature was tested by RT-PCR [Bomben, Haematologica 2018], somatic mutations by high-throughput targeted resequencing.[Ferrero, EHA 2017]. The optimal cut-off value for FC was determined by applying receiver operating curve (ROC) analysis. Survival analyses were performed by both univariate (UV) and multivariate (MV) Cox modeling via R (v.3.5.2): the variables showing a p < 0.2 after UV were selected for the MV, including cases with missing values.

Back to Top | Article Outline


Among the 300 enrolled patients the MIPI scored 60% low, 24% intermediate and 16% high. Overall, 233/296 (79%) patients presented at baseline bone marrow (BM) infiltration (inf), for a median FC value of 7% (0.01-93) and 4% in peripheral blood, PB (0.02-92). 250/300 (83%) showed a molecular marker for MRD and 211 (84%) an available IGH sequence: IGHV3-21 (21%), IGHV4-34 (16%) and IGHV3-7 (8%) were the most frequent rearrangements. Median IGH homology was 99.2% (89.9-100), with 163 cases (77%) above the 98% cut-off (UM). 22 (10%) showed a stereotyped IGH. 84/271 patients (31%) showed Ki-67≥30%, 167/183 (92%) SOX11+, 27/300 (9%) blastoid histology (B-hist), 15/186 (8%) TP53, 23/186 (12%) KMT2D and 14/186 (8%) NOTCH1 mutations (mut), 40/83 (48%) “BCR-high” signature. After a median follow-up of 51 months, several baseline biopredictors negatively impacted PFS in UV: BMinf, high FC-BM/PB, MRD marker+, IGH-UM, Ki-67≥30%, B-hist, TP53 and KMT2D mut, “BCR-high” signature. No significant outcome discrimination could be made on the basis of stereotyped IGH or SOX11 staining. After MV BMinf, IGH-UM, B-hist, TP53/KMT2D mut remained significant, as opposed to MIPI. Similar results were reported for OS by UV, indicating FC-BM/PB, Ki-67≥30%, B-hist, TP53/KMT2D mut as significant predictors. Finally, after MV, Ki-67≥30%, B-hist and KMT2D mut remained significant for OS, as opposed to MIPI (Table1).



Back to Top | Article Outline


This is the first comprehensive analysis of the clinical impact of a composite panel of easily implementable biopredictors in a multicenter, prospective, clinical trial for MCL patients. Several variables maintain their independent prognostic value, underlining the biological complexity of MCL. Notably, all these biomarkers are of relative simple and applicable determination. Interestingly, the biological predictors outperformed the predictive value of clinical predictors, such as MIPI, suggesting that biological features are the key drivers of outcome in MCL.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.